/Investor DB

Commodore Capital

Venture capital

New York · Series C–Late Stage · 16 people tracked

Find your way into Commodore Capital

1,698 people in our graph share verified history with the Commodore Capital team — schools, employers, funds. One of them is your warm intro.

Parth Chopraunlockedknows Logan Brock · together at Global Platinum Securities (overlapped)
knows the team · via Roivant Sciences
×3knows the team · via Longitude Capital
×4knows the team · via New York-Presbyterian Hospital
×3knows the team · via Venrock
✨ Fox Verdict
Sign up to see your fit

Investment thesis

Commodore Capital believes the biopharmaceutical industry is in the early stages of a major innovation cycle, driven by scientific discoveries translating into clinical breakthroughs through novel therapeutic modalities such as genetic medicines and cellular therapies. The firm notes that innovation has shifted from large pharmaceutical companies to smaller biopharmaceutical firms. Commodore aims to be a supportive partner to these companies as they work to bring safe and effective new medicines to patients worldwide.

Source: firm website, verified Sep 29, 2026.

What founders say

No founder feedback on Commodore Capital yet.

Stage
Series C–Late Stage
HQ
New York, New York, US
Leads rounds
Follows
Instruments
Equity
Founded
2019
Last 12 months
5 investments
AUM
$2.4B
Tracked investments
12
IPOs
3
Acquisitions
1

Team · 16 people

from the firm's website & curated & public directories

What they invest in

from 12 of 12 portfolio companies

Biotech ×7AI & Machine Learning ×2Enterprise Software ×2Healthtech ×2SaaS ×2Consumer ×1Crypto & Web3 ×1Deep Tech ×1

HQs:United States×7Finland×1Indonesia×1Portugal×1

Investments · 12 tracked

founders shown can be your intro path

By year:2026 · 32025 · 22024 · 12021 · 32020 · 110 dated

Agenusagenusbio.comNASDAQ: AGENAug 2026

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in

Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalInvusLigand Pharmaceuticals+1 more

Damora TherapeuticsNASDAQ: DMRANov 2025 · $284.9M

Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.

BiotechCopenhagen, US

Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)

Co-investorsAccess BiotechnologyAndreessen HorowitzBAM ElevateBay City CapitalEIR VenturesForbion+7 more

Relmada Therapeuticsrelmada.comNASDAQ: RLMDMar 2026

Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.

BiotechHealthtechNew York, US

Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)

Co-investorsBioAdvanceBAM ElevateBraidwellJanus Henderson InvestorsOrbiMedRA Capital+2 more

AirHelpairhelp.comin𝕏Series B

AirHelp provides technology to help air passengers claim compensation for delayed and cancelled flights.

ConsumerLegalTechSaaSTravel & HospitalityLisbon, PT

Henrik Zillmer(Founder)inNicolas Michaelsen(Founder)inGreg Roodt(Founder/CTO)inTomasz Pawliszyn(CEO)in

Co-investorsABRY PartnersTempoCapUpslope VenturesY Combinator10x Founders10x Group+11 more

Athiraathira.comDec 2025

A biotechnology company developing new therapies for patients with high unmet medical needs.

Biotech

Co-investorsDolby Family VenturesLifeSci Venture PartnersSofinnova VenturesThe W FundFranklin TempletonLigand Pharmaceuticals+5 more

IDRXidrx.co𝕏Aug 2024 · $120M

IDRX is a regulated stablecoin backed 1:1 by the Indonesian Rupiah, letting users hold and transfer IDR value on blockchain networks for payments, trading, and Web3 financial activity.

Crypto & Web3Fintech

Co-investorsMDI VenturesRA Capital

Kronos Biokronosbio.cominAug 2020 · $155M

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsEcoR1 CapitalGV (Google Ventures)Nextech InvestVida VenturesBlackRockInvus+2 more

Nimbusnimbus.energyJul 2021 · $105M

Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.

Deep TechEnergyHardware

Michael Gorman(Founder)in

Co-investorsFoothill VenturesAccess BiotechnologyAtlas VentureBain Capital Life SciencesBiotechnology Value FundGV (Google Ventures)+2 more

Nimbusnimbusweb.mein𝕏Jul 2021 · $105M

FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US

Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)

Co-investorsPre-Seed to SucceedYellow Rocks!Access BiotechnologyAtlas VentureBain Capital Life SciencesBiotechnology Value Fund+3 more

Speechlyspeechly.comin𝕏Seedacquired by Roblox

Speechly provides an API that performs speech recognition and language understanding directly on user devices, reducing costs for applications that need to analyze spoken interactions in real time.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareHelsinki, FI

Otto Soderlund(Founder)inHannes Heikinheimo(Founder)in

Co-investorsCherry VenturesSNÖ VenturesTq Ventures LlcY Combinator10X CapitalAtypical Ventures+6 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Ollin Biosciences, Inc.Shoreline Biosciences

Exits · 4

3 IPOs · 1 acquisitions

AgenusNASDAQ: AGENDamora TherapeuticsNASDAQ: DMRARelmada TherapeuticsNASDAQ: RLMDSpeechlyacq. by Roblox

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has Commodore Capital made?
Commodore Capital has 12 tracked investments, 4 of which have exited, including 5 dated in the last 24 months.
What stage does Commodore Capital invest at?
Commodore Capital invests at the Series C, Late Stage stages.
What sectors does Commodore Capital focus on?
Commodore Capital focuses on Biotech.
Where is Commodore Capital located?
Commodore Capital is headquartered in New York, US.
Does Commodore Capital lead rounds?
Commodore Capital typically participates in rounds rather than leading them.

Similar investors

Featured in lists